PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32934724-4 2020 The direct mechanisms of metformin include inhibition of the LKB1-AMP-activated protein kinase-mTOR, PI3K-Akt and insulin-like growth factor 1-related signaling pathways, which reduces the proliferation and promotes the apoptosis of EC cells. Metformin 25-34 insulin like growth factor 1 Homo sapiens 114-142 33831975-6 2022 Metformin may reduce the risk of BPH by inhibiting the insulin-like growth factor 1 pathway and some but not all studies suggest a protective role of metformin on the risk of PCa. Metformin 0-9 insulin like growth factor 1 Homo sapiens 55-83 33227290-9 2021 We therefore hypothesised that the effect of metformin in vivo was not due to direct cytotoxicity on cancer cells, but by modulation of IGF-1 expression. Metformin 45-54 insulin like growth factor 1 Homo sapiens 136-141 33713207-5 2021 On the other hand, metformin, an anti-hyperglycemic drug that decreases serum levels of insulin and IGF-1, could have a protective role in the treatment of endocrine tumors. Metformin 19-28 insulin like growth factor 1 Homo sapiens 100-105 33884414-10 2021 Compared to the self-directed group, participants in metformin had significant decreases on IGF-1 (mean difference in change: -5.50 ng/ml, p=0.02) and IGF1:IGFBP3 molar ratio (mean difference in change: -0.0119, p=0.011) at 3 months. Metformin 53-62 insulin like growth factor 1 Homo sapiens 92-97 33884414-10 2021 Compared to the self-directed group, participants in metformin had significant decreases on IGF-1 (mean difference in change: -5.50 ng/ml, p=0.02) and IGF1:IGFBP3 molar ratio (mean difference in change: -0.0119, p=0.011) at 3 months. Metformin 53-62 insulin like growth factor 1 Homo sapiens 151-155 33884414-14 2021 CONCLUSIONS: In cancer survivors with obesity, metformin may have a short-term effect on IGF-1 reduction that wanes over time. Metformin 47-56 insulin like growth factor 1 Homo sapiens 89-94 31816435-0 2020 The influence of metformin on IGF-1 levels in humans: A systematic review and meta-analysis. Metformin 17-26 insulin like growth factor 1 Homo sapiens 30-35 31628524-8 2019 Metformin effectively inhibited the increase of IGF-1 and maintained the IGFBP-1. Metformin 0-9 insulin like growth factor 1 Homo sapiens 48-53 31886264-8 2019 The effect of metformin on hyperglycemia decreases intracellular reactive oxygen species (ROS) and advanced glycation end-products (AGEs) in collagen, and reduced serum levels of insulin-like growth factors (IGF-1) were beneficial for bone formation. Metformin 14-23 insulin like growth factor 1 Homo sapiens 208-213 31816435-8 2020 Moreover, in age 18 < years older metformin intake (WMD: 15.125 ng/ml, 95 % CI: 5.522, 24.729, I2 = 92.5 %) significantly increased IGF-1 than 18 <= years older (WMD:-1.038 ng/ml, 95 % CI: -3.578,1.502,I2 = 78.0 %). Metformin 34-43 insulin like growth factor 1 Homo sapiens 132-137 31816435-9 2020 Following dose-response evaluation, metformin intake reduced IGF-1 (coefficient for dose-response analysis= -13.14, P = 0.041 and coefficient for liner analysis= -0.066, P = 0.038) significantly based on treatment duration. Metformin 36-45 insulin like growth factor 1 Homo sapiens 61-66 31816435-10 2020 CONCLUSION: We found in children, intervention duration <12 weeks yielded significant reductions in IGF-1, whilst paradoxically, in participants >18 years old, metformin intake significantly increased IGF-1. Metformin 160-169 insulin like growth factor 1 Homo sapiens 201-206 31816435-1 2020 BACKGROUND: A meta-analysis is needed to comprehensively consolidate findings from the influence of metformin on IGF-1 levels. Metformin 100-109 insulin like growth factor 1 Homo sapiens 113-118 31816435-2 2020 The present study was conducted with the objective to accurately evaluate the influence of metformin intake on IGF-1 levels via a meta-analysis of randomized controlled trials. Metformin 91-100 insulin like growth factor 1 Homo sapiens 111-116 31816435-4 2020 Weighted mean difference (WMD) with the 95 % CI were applied for estimating the effects of metformin on serum IGF-1 levels. Metformin 91-100 insulin like growth factor 1 Homo sapiens 110-115 31816435-6 2020 Pooled results demonstrated an overall non-significant decline in IGF-1 following metformin intake (WMD: -8.292 ng/ml, 95 % CI: -20.248, 3.664, p = 0.174) with heterogeneity among (p = 0.000,I2 = 87.1 %). Metformin 82-91 insulin like growth factor 1 Homo sapiens 66-71 26902691-7 2016 Metformin resulted in a significant reduction of IGF-1, IGF-1: IGFBP-3 molar ratio, insulin, FBG and HOMA-IR. Metformin 0-9 insulin like growth factor 1 Homo sapiens 49-54 30147674-5 2018 Lowering insulin and insulin-like growth factor 1 (IGF-1) levels that stimulate cancer growth could be important features of metformin"s mode of action. Metformin 125-134 insulin like growth factor 1 Homo sapiens 21-49 30147674-5 2018 Lowering insulin and insulin-like growth factor 1 (IGF-1) levels that stimulate cancer growth could be important features of metformin"s mode of action. Metformin 125-134 insulin like growth factor 1 Homo sapiens 51-56 29241458-9 2017 IGF1, IGF1R, AKT p-IGF1, p-IGF1R, and p-Akt protein expression was enhanced dose-dependently with metformin, and was also significantly changed by treatment of CP70 cells with 0 mM metformin +10 mM LY294002. Metformin 98-107 insulin like growth factor 1 Homo sapiens 0-4 29241458-9 2017 IGF1, IGF1R, AKT p-IGF1, p-IGF1R, and p-Akt protein expression was enhanced dose-dependently with metformin, and was also significantly changed by treatment of CP70 cells with 0 mM metformin +10 mM LY294002. Metformin 98-107 insulin like growth factor 1 Homo sapiens 6-10 29241458-9 2017 IGF1, IGF1R, AKT p-IGF1, p-IGF1R, and p-Akt protein expression was enhanced dose-dependently with metformin, and was also significantly changed by treatment of CP70 cells with 0 mM metformin +10 mM LY294002. Metformin 181-190 insulin like growth factor 1 Homo sapiens 0-4 29241458-10 2017 Moreover, changes in the expression of MRP2, IGF1, IGF1R, and AKT was metformin-concentration dependent, and was significantly different from that in the untreated control group (P < 0.05). Metformin 70-79 insulin like growth factor 1 Homo sapiens 45-49 28927103-3 2017 Metformin decreases the levels of insulin-like growth factor 1 and secondarily inhibits the mammalian target of rapamycin pathway to exhibit anticancer effects. Metformin 0-9 insulin like growth factor 1 Homo sapiens 34-62 27745917-11 2016 After metformin, there were significant decreases in serum IGF-1 (p=0.046), omentin (p=0.007), insulin (p=0.012), C-peptide (p=0.018), and leptin (p=0.0035). Metformin 6-15 insulin like growth factor 1 Homo sapiens 59-64 27293994-8 2016 Treating EC with siYAP/TAZ, YAP inhibitor Verteporfin or metformin alone only partially inhibited the function of insulin and IGF1. Metformin 57-66 insulin like growth factor 1 Homo sapiens 126-130 28196954-4 2017 Multiple studies in vitro and in vivo have demonstrated that metformin can inhibit the growth of thyroid cells and different types of thyroid cancer cells by affecting the insulin/IGF1 and mTOR pathways. Metformin 61-70 insulin like growth factor 1 Homo sapiens 180-184 28253329-12 2017 Metformin (5mM) abrogated the proliferation of benign prostatic epithelial cells induced by IGF-1. Metformin 0-9 insulin like growth factor 1 Homo sapiens 92-97 28253329-16 2017 CONCLUSIONS: Our study demonstrates that metformin inhibits the proliferation of benign prostatic epithelial cells by suppressing the expression of IGF-1R and IGF-1 secretion in stromal cells. Metformin 41-50 insulin like growth factor 1 Homo sapiens 148-153 27654259-0 2016 Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer. Metformin 129-138 insulin like growth factor 1 Homo sapiens 0-28 27654259-7 2016 RESULTS: We found that high IGF-1 plasma concentrations in women with EC were reversed by conventional antidiabetic doses of metformin in the present work. Metformin 125-134 insulin like growth factor 1 Homo sapiens 28-33 27144340-0 2016 Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway. Metformin 0-9 insulin like growth factor 1 Homo sapiens 112-116 27144340-6 2016 Furthermore, the addition of IGF-1 to crizotinib-sensitive H2228 cells induced crizotinib resistance, which was overcome by metformin. Metformin 124-133 insulin like growth factor 1 Homo sapiens 29-34 26902691-7 2016 Metformin resulted in a significant reduction of IGF-1, IGF-1: IGFBP-3 molar ratio, insulin, FBG and HOMA-IR. Metformin 0-9 insulin like growth factor 1 Homo sapiens 56-61 27009398-7 2016 Finally, when compared to untreated type 2 diabetes patients, the metformin-treated diabetic patients showed increased IGFBP-2 levels with diminished serum IGF-1 levels. Metformin 66-75 insulin like growth factor 1 Homo sapiens 156-161 26995937-8 2015 RESULTS: The presence of transcripts of three types of IGF-1 isoforms was observed in healthy controls and PCOS patients, regardless of metformin treatment. Metformin 136-145 insulin like growth factor 1 Homo sapiens 55-60 25862373-10 2015 IGF-1 activated both ERK1/2 and Akt, but these effects were attenuated by metformin treatment. Metformin 74-83 insulin like growth factor 1 Homo sapiens 0-5 25687657-9 2015 Higher concentrations of metformin lead to a significant (p < 0.05) dose-dependent attenuation of the progesterone effect with regard to IGFBP-1, -3, -5, -6, as well as IGF I receptor, while it did not change the expression of IGFBP-2 and -4, IGF I and II and the IGF II receptor. Metformin 25-34 insulin like growth factor 1 Homo sapiens 246-258 26514337-13 2015 Her serum insulin-like growth factor-1 level, measured after glycemic control was achieved with metformin and insulin, was elevated, which is characteristic of acromegaly. Metformin 96-105 insulin like growth factor 1 Homo sapiens 10-38 25862373-12 2015 Our results suggest that metformin is a potent inhibitor of the IGF-1/IGF-1R system and may be beneficial in prostate cancer treatment. Metformin 25-34 insulin like growth factor 1 Homo sapiens 64-69 24437490-11 2014 By inhibiting androgen-dependent IGF-IR up-regulation, metformin reduced IGF-I-mediated proliferation of LNCaP cells. Metformin 55-64 insulin like growth factor 1 Homo sapiens 33-38 25640355-0 2015 Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R. Metformin 0-9 insulin like growth factor 1 Homo sapiens 65-70 25640355-3 2015 However, the IGF-1 level in the medium of cultured cells after treatment with metformin was decreased (p<0.05). Metformin 78-87 insulin like growth factor 1 Homo sapiens 13-18 25640355-5 2015 In summary, metformin can reduce the secretion of IGF-1 by Ishikawa and JEC EC cell lines and their expression of IGF-1R to deactivate downstream signaling involving the PI-3K/Akt pathway to inhibit endometrial carcinoma cell growth. Metformin 12-21 insulin like growth factor 1 Homo sapiens 50-55 25253174-5 2014 The ki-67 response to metformin was assessed comparing data obtained from baseline biopsy (ki-67 and tumor subtype) and serum markers (HOMA index, C-peptide, IGF-I, IGFBP-1, IGFBP-3, free IGF-I, hs-CRP, adiponectin) with the same measurements at definitive surgery. Metformin 22-31 insulin like growth factor 1 Homo sapiens 158-163 25253174-5 2014 The ki-67 response to metformin was assessed comparing data obtained from baseline biopsy (ki-67 and tumor subtype) and serum markers (HOMA index, C-peptide, IGF-I, IGFBP-1, IGFBP-3, free IGF-I, hs-CRP, adiponectin) with the same measurements at definitive surgery. Metformin 22-31 insulin like growth factor 1 Homo sapiens 188-193 25253174-7 2014 Compared with placebo, metformin significantly decreased ki-67 in women with HOMA > 2.8, those in the lowest IGFBP-1 quintile, those in the highest IGFBP-3 quartile, those with low free IGF-I, those in the top hs-CRP tertile, and those with HER2-positive tumors. Metformin 23-32 insulin like growth factor 1 Homo sapiens 189-194 25305450-8 2015 IGF-I blocked metformin-induced MM cell apoptosis and reactivation of the PI3K/AKT/mTOR signaling pathway. Metformin 14-23 insulin like growth factor 1 Homo sapiens 0-5 25688512-4 2014 Metformin has recently shown some anti-cancer activity in both in vitro and in vivo studies by its indirect properties to decrease insulin and insulin-like growth factor-1 (IGF-1) levels and by its antitumour effect to promote AMPK activation and consequently inhibition to TSC1-2/mTOR complex. Metformin 0-9 insulin like growth factor 1 Homo sapiens 143-171 25688512-4 2014 Metformin has recently shown some anti-cancer activity in both in vitro and in vivo studies by its indirect properties to decrease insulin and insulin-like growth factor-1 (IGF-1) levels and by its antitumour effect to promote AMPK activation and consequently inhibition to TSC1-2/mTOR complex. Metformin 0-9 insulin like growth factor 1 Homo sapiens 173-178 24972190-10 2014 Mean plasma insulin (p=0.0005), IGF-1 (p=0.001), and IGFBP-7 (p=0.0098) were significantly reduced after metformin treatment. Metformin 105-114 insulin like growth factor 1 Homo sapiens 32-37 24437490-12 2014 These results indicate that, in prostate cancer cells, metformin inhibits IGF-I-mediated biological effects by disrupting membrane-initiated AR action responsible for IGF-IR up-regulation and suggest that metformin could represent a useful adjunct to the classical antiandrogen therapy. Metformin 55-64 insulin like growth factor 1 Homo sapiens 74-79 24437490-12 2014 These results indicate that, in prostate cancer cells, metformin inhibits IGF-I-mediated biological effects by disrupting membrane-initiated AR action responsible for IGF-IR up-regulation and suggest that metformin could represent a useful adjunct to the classical antiandrogen therapy. Metformin 205-214 insulin like growth factor 1 Homo sapiens 74-79 23663483-9 2013 The anti-proliferative actions of metformin were associated with an activation of AMP-activated protein kinase AMPKThr172 together with an inhibition of the insulin/insulin-like growth factor-I (IGF-I) receptor activation and downstream signalling mediators IRS-1 and phosphorylated Akt. Metformin 34-43 insulin like growth factor 1 Homo sapiens 157-193 23794020-3 2013 These results have drawn attention to the mechanisms underlying metformin"s anti-cancer effects, which may include triggering of the AMP-activated protein kinase (AMPK) pathway, resulting in vulnerability to an energy crisis (leading to cell death under conditions of nutrient deprivation) and a reduction in circulating insulin/IGF-1 levels. Metformin 64-73 insulin like growth factor 1 Homo sapiens 329-334 24603137-0 2014 Human granulosa cells: insulin and insulin-like growth factor-1 receptors and aromatase expression modulation by metformin. Metformin 113-122 insulin like growth factor 1 Homo sapiens 35-63 23663483-11 2013 In contrast, exposure to high glucose levels promoted a more robust IGF-I response and Akt activation which correlated to stimulated AMPKSer485 phosphorylation and impaired AMPKThr172 phosphorylation, resulting in reduced anti-proliferative and apoptotic effects by metformin. Metformin 266-275 insulin like growth factor 1 Homo sapiens 68-73 23663483-13 2013 However, hyperglycaemic conditions enhance the insulin/IGF-I responses resulting in an altered AMPK activation profile and prevent metformin from fully switching off the growth promoting signals in pancreatic cancer cells. Metformin 131-140 insulin like growth factor 1 Homo sapiens 55-60 23620761-0 2013 Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. Metformin 0-9 insulin like growth factor 1 Homo sapiens 36-41 21946410-0 2011 IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. Metformin 135-144 insulin like growth factor 1 Homo sapiens 0-4 22038047-0 2012 Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells. Metformin 28-37 insulin like growth factor 1 Homo sapiens 59-63 22038047-2 2012 Since caveolin-1 (Cav-1) plays a role in AMPK activation and energy balance, we investigated whether Cav-1 could participate in metformin"s inhibitory effect on IGF1 signaling. Metformin 128-137 insulin like growth factor 1 Homo sapiens 161-165 22038047-4 2012 In Calu-1, but not in Calu-6 cells, metformin reduced phosphorylation of type 1 insulin-like growth factor receptor (IGF-IR) substrates Akt and Forkhead transcription factor 3a (FOXO3a), inhibited IGF1-dependent FOXO3a nuclear exit, and decreased IGF1-dependent cell proliferation. Metformin 36-45 insulin like growth factor 1 Homo sapiens 197-201 22038047-4 2012 In Calu-1, but not in Calu-6 cells, metformin reduced phosphorylation of type 1 insulin-like growth factor receptor (IGF-IR) substrates Akt and Forkhead transcription factor 3a (FOXO3a), inhibited IGF1-dependent FOXO3a nuclear exit, and decreased IGF1-dependent cell proliferation. Metformin 36-45 insulin like growth factor 1 Homo sapiens 247-251 22038047-6 2012 Cav-1 silencing in Calu-1 and overexpression in Calu-6 reduced and improved, respectively, the inhibitory effect of metformin on IGF1-dependent Akt phosphorylation. Metformin 116-125 insulin like growth factor 1 Homo sapiens 129-133 18319306-7 2008 RESULTS: Metformin-treated girls gained on average 5.5 kg (or approximately 50%) less fat, after 4 yr were less insulin resistant and less hyperandrogenic, had lower IGF-I levels and a less atherogenic lipid profile, and were less likely to be post-menarcheal than untreated girls, whereas their gain in height, lean mass, and bone mineral density were similar. Metformin 9-18 insulin like growth factor 1 Homo sapiens 166-171 21664031-1 2011 OBJECTIVE: To assess the effects of metformin on insulin-, IGF I-, and IGF II-receptor gene expression and Akt phosphorylation in decidualized human endometrial stromal cells (ESC) after stimulation with insulin, IGF I and II. Metformin 36-45 insulin like growth factor 1 Homo sapiens 71-76 20388847-6 2010 Recent results show that metformin-induced activation of AMPK disrupts crosstalk between insulin/IGF-1 receptor and GPCR signaling in pancreatic cancer cells and inhibits the growth of these cells in xenograft models. Metformin 25-34 insulin like growth factor 1 Homo sapiens 97-102 20388847-9 2010 We posit that crosstalk between insulin/IGF-1 receptor and GPCR signaling is a mechanism for promoting the development of certain types of cancer and a target for the prevention and therapy of these diseases via metformin administration. Metformin 212-221 insulin like growth factor 1 Homo sapiens 40-45 18256928-9 2009 Metformin treatment was sufficient, however, to reduce systemic IGF-1 and the proliferation rate of tumor cells in vascularized regions. Metformin 0-9 insulin like growth factor 1 Homo sapiens 64-69 21664031-0 2011 Does metformin influence the insulin-, IGF I- and IGF II-receptor gene expression and Akt phosphorylation in human decidualized endometrial stromal cells? Metformin 5-14 insulin like growth factor 1 Homo sapiens 39-44 21664031-1 2011 OBJECTIVE: To assess the effects of metformin on insulin-, IGF I-, and IGF II-receptor gene expression and Akt phosphorylation in decidualized human endometrial stromal cells (ESC) after stimulation with insulin, IGF I and II. Metformin 36-45 insulin like growth factor 1 Homo sapiens 59-64 20363874-3 2010 The AMPK activator metformin stimulated AMPK Thr172 phosphorylation and inhibited IGF-I-stimulated phosphorylation of Akt/tuberous sclerosis 2 (TSC2)/mammalian target of rapamycin (mTOR)/p70S6 kinase (p70S6K). Metformin 19-28 insulin like growth factor 1 Homo sapiens 82-87 19709092-8 2009 Metformin treatment, and diets low in milk protein content and glycaemic index reduce increased IGF-1 signalling. Metformin 0-9 insulin like growth factor 1 Homo sapiens 96-101 17350746-0 2008 Effect of metformin on IGF-1 and IGFBP-1 levels in obese patients with polycystic ovary syndrome. Metformin 10-19 insulin like growth factor 1 Homo sapiens 23-28 16492692-9 2006 Metformin was also associated with lower insulin resistance and leptin and IGF-I levels and higher SHBG and IGF-binding protein-1 levels and with a more favorable lipid profile. Metformin 0-9 insulin like growth factor 1 Homo sapiens 75-80 16516166-7 2006 Moreover, AICAR and metformin inhibited the ability of insulin and IGF-1 to induce HIF-1alpha expression. Metformin 20-29 insulin like growth factor 1 Homo sapiens 67-72 15697073-5 2004 The mean IGF-I levels decreased significantly on metformin therapy. Metformin 49-58 insulin like growth factor 1 Homo sapiens 9-14 15697073-7 2004 Only the change in serum levels of progesterone and IGF-I on metformin were statistically significant between responders and non-responders; metformin-induced decremental change in IGF-I levels were greater in responders. Metformin 61-70 insulin like growth factor 1 Homo sapiens 52-57 15697073-7 2004 Only the change in serum levels of progesterone and IGF-I on metformin were statistically significant between responders and non-responders; metformin-induced decremental change in IGF-I levels were greater in responders. Metformin 141-150 insulin like growth factor 1 Homo sapiens 181-186 15697073-9 2004 By decreasing insulin and IGF-I levels, metformin therapy offers additional beneficial effects in resumption of regular menses. Metformin 40-49 insulin like growth factor 1 Homo sapiens 26-31 15697073-10 2004 Thus, in PCOS patients with elevated levels of IGF-I, metformin may be considered as an appropriate agent to be used for the regulation of menstrual cycles. Metformin 54-63 insulin like growth factor 1 Homo sapiens 47-52 11912566-8 2002 Also, metformin reduced the concentration of plasma glucose (P =.011), serum insulin (P=.044), and serum insulin-like growth factor -1 (IGF-1) (P=.013), while it increased serum glucagon concentration (P <.001). Metformin 6-15 insulin like growth factor 1 Homo sapiens 105-134 15063962-2 2004 This study was designed to evaluate effects of metformin therapy on serum levels of IGFBP-1 and IGF-I. Metformin 47-56 insulin like growth factor 1 Homo sapiens 96-101 15063962-10 2004 CONCLUSIONS: The present study shows that metformin therapy not only restores normal levels of insulin and testosterone, but also decreases the pool of free-bioactive IGF-I by increasing the levels of circulating IGFBP-1. Metformin 42-51 insulin like growth factor 1 Homo sapiens 167-172 12788862-12 2003 Baseline GH hypersecretion and elevated serum IGF-1 normalized after 6 months on flutamide-metformin. Metformin 91-100 insulin like growth factor 1 Homo sapiens 46-51 11912566-8 2002 Also, metformin reduced the concentration of plasma glucose (P =.011), serum insulin (P=.044), and serum insulin-like growth factor -1 (IGF-1) (P=.013), while it increased serum glucagon concentration (P <.001). Metformin 6-15 insulin like growth factor 1 Homo sapiens 136-141 10770203-1 2000 The objective of the present study was to investigate whether metformin affected plasma concentrations of insulin-like growth factor (IGF) I and IGF-binding protein I (IGFBP-I) in polycystic ovary syndrome (PCOS) patients. Metformin 62-71 insulin like growth factor 1 Homo sapiens 106-140 11239532-11 2001 Metformin led to modulation of preovulatory of follicular fluid IGF levels with increases of IGF-I (140 +/- 8 vs. 109 +/- 7ng/mL) and decreased of IGFBP-1 (133 +/- 8 vs.153 +/- 9ng/mL). Metformin 0-9 insulin like growth factor 1 Homo sapiens 93-98 11549648-9 2001 The latter finding may be due to an IGF-I-reducing effect of metformin, as after 14 d of metformin treatment baseline levels of IGF-I were significantly lower than in the placebo condition (236.9 +/- 13.9 vs. 263.2 +/- 14.4 microg/liter; P = 0.015). Metformin 61-70 insulin like growth factor 1 Homo sapiens 36-41 11549648-9 2001 The latter finding may be due to an IGF-I-reducing effect of metformin, as after 14 d of metformin treatment baseline levels of IGF-I were significantly lower than in the placebo condition (236.9 +/- 13.9 vs. 263.2 +/- 14.4 microg/liter; P = 0.015). Metformin 61-70 insulin like growth factor 1 Homo sapiens 128-133 11549648-9 2001 The latter finding may be due to an IGF-I-reducing effect of metformin, as after 14 d of metformin treatment baseline levels of IGF-I were significantly lower than in the placebo condition (236.9 +/- 13.9 vs. 263.2 +/- 14.4 microg/liter; P = 0.015). Metformin 89-98 insulin like growth factor 1 Homo sapiens 128-133 10770203-7 2000 A nonsignificant increase in plasma IGF-I levels was observed after metformin (276 +/-48 vs. 291 +/- 71 mcg/L), with a significant increase in plasma IGFBP-I levels (0.56 +/- 0.2 vs. 0.98 +/- 0.38 mcg/L; P < 0.05). Metformin 68-77 insulin like growth factor 1 Homo sapiens 36-41 35125086-8 2022 Coadministration of nimbolide with metformin and the chemotherapeutic drugs tamoxifen/cisplatin displayed higher efficacy than single agents in inhibiting IGF-1/PI3K/Akt/AR signaling. Metformin 35-44 insulin like growth factor 1 Homo sapiens 155-160 35142713-1 2022 PURPOSE: To determine the separated and combined effects of metformin and resistance exercise on glycemic control, insulin sensitivity and insulin-like growth factor 1 (IGF-1) in overweight/obese individuals with pre-and-T2DM. Metformin 60-69 insulin like growth factor 1 Homo sapiens 139-167 35142713-1 2022 PURPOSE: To determine the separated and combined effects of metformin and resistance exercise on glycemic control, insulin sensitivity and insulin-like growth factor 1 (IGF-1) in overweight/obese individuals with pre-and-T2DM. Metformin 60-69 insulin like growth factor 1 Homo sapiens 169-174 35142713-9 2022 Metformin decreased serum IGF-1 concentrations (P = 0.006) and RT did not reverse this reduction. Metformin 0-9 insulin like growth factor 1 Homo sapiens 26-31 35072253-4 2022 The mechanism of the antitumor action of metformin is pleiotropic and involves several signalling pathways, including AMPK/mTOR (mitogen activated protein kinase/mammalian target rapamycin), STAT3 (signal transducer and activator of transcription) and numerous factors: NF-KB (nuclear factor kappa), HIF-1 alpha (hypoxia inducible factor 1), IGF-1 (insulin-like growth factor-1), which affect cell proliferation and apoptosis. Metformin 41-50 insulin like growth factor 1 Homo sapiens 342-347 35072253-4 2022 The mechanism of the antitumor action of metformin is pleiotropic and involves several signalling pathways, including AMPK/mTOR (mitogen activated protein kinase/mammalian target rapamycin), STAT3 (signal transducer and activator of transcription) and numerous factors: NF-KB (nuclear factor kappa), HIF-1 alpha (hypoxia inducible factor 1), IGF-1 (insulin-like growth factor-1), which affect cell proliferation and apoptosis. Metformin 41-50 insulin like growth factor 1 Homo sapiens 349-377